The REMODEL trial testing semaglutide’s efficacy in patients with CKD and T2DM also employed MRI, transcriptomics, blood and urine samples, and kidney biopsies to clarify the drug’s effects.
DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, and Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback